# NEULANDLAB (NEULANDLAB) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/neulandlab

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹22,890
- Change: +0.99%
- As of: 2026-09-18
- 1D return: +0.77%
- 5D return: -4.03%
- 1M return: -3.09%
- Latest complete quarter: fy27_q1

## Faxioms Analysis

_As of 2026-09-18_

### Technical Outlook

As of September 18, 2026, NEULANDLAB's technical stance presents a mixed picture across different timeframes. The daily timeframe shows the price below the 20-day and 20-day simple moving averages (SMAs), suggesting short-term caution, despite being above the 50-day SMA and the Supertrend indicator. In contrast, the weekly and monthly timeframes exhibit stronger alignment with the bullish trend, with the price trading above key moving averages and the Supertrend indicator. Recent formations include an active Outside Bar on the daily timeframe, alongside a Harami and Doji pattern on the monthly timeframe, indicating potential shifts in momentum. The stock is currently positioned closer to its 252-day range high (89%) than its low (18%), with a current drawdown of -5% from a recent peak. The annualized volatility stands at 46%, with an Average True Range (ATR) of 3.29% of the current price.

Nearest support is observed around ₹22,723.33 (pivot level), followed by ₹22,526.0. Overhead resistance is noted at ₹22,921.67, with further levels at ₹23,178.33 and ₹23,376.67. The stock has experienced recent wide intraday ranges, including a notable upward move on September 8, 2026, and a downward move on September 9, 2026, both with high severity.

Key watch conditions include monitoring the price action relative to the ₹22,921.67 resistance level. A sustained move above this could signal renewed upward momentum. Conversely, a break below the ₹22,723.33 support level may indicate further consolidation or a shift in the short-term trend.

- Daily timeframe shows price below 20-day and 20-day SMAs, while weekly and monthly timeframes remain bullish.
- Nearest support levels are at ₹22,723.33 and ₹22,526.0.
- Nearest resistance levels are at ₹22,921.67 and ₹23,178.33.
- Active daily pattern: Outside Bar (as of 2026-09-18).
- Watch for a break above ₹22,921.67 for potential upside confirmation or a break below ₹22,723.33 as a cautionary signal.

- Harami
- Doji
- Outside Bar
- Inside Bar
- Evening Star

### News Context

Neuland Laboratories announced on September 15, 2026, that its first commercial peptide manufacturing module has become operational. This facility is designed to expand the company's peptide manufacturing capabilities. The second module is planned to have a total reactor capacity of up to 18,000 litres, incorporating various sizes of LPPS and SPPS reactors, along with smaller reactors. Separately, a report on September 15, 2026, discussed investor Vijay Kedia's stock-picking strategy, highlighting his focus on discipline, willingness to buy after sharp declines, and a growing interest in Small and Medium Enterprises (SMEs), unlisted companies, and startups for attractive valuations and growth potential.

- Neuland Laboratories' first commercial peptide manufacturing module became operational on September 15, 2026.
- The company's second peptide manufacturing module is planned to feature a total reactor capacity of up to 18,000 litres.
- The second module will include multiple LPPS reactors (three 5,000-litre) and SPPS reactors (one 1,000-litre or 2,000-litre), as well as smaller reactors.
- A September 15, 2026 report detailed investor Vijay Kedia's 'RISE' strategy, emphasizing discipline and a focus on SMEs, unlisted companies, and startups.

- Neuland Labs' first commercial peptide manufacturing module goes operational; Stock sees profit booking
- Vijay Kedia reveals multibagger playbook: How the superstar picks stocks using RISE strategy

### What Changed

As of September 18, 2026, Neuland Laboratories' stock price has seen a slight increase, moving from ₹22,665.0 to ₹22,840.0. The available evidence does not indicate any new filings or news developments that would explain this recent price movement. The company's profile on the NSE remains unchanged.

- Stock price increased from ₹22,665.0 to ₹22,840.0 between the previous observation and September 18, 2026.
- No new filings were reported for Neuland Laboratories as of September 18, 2026.
- No news developments were reported for Neuland Laboratories as of September 18, 2026.
- Neuland Laboratories is listed on the NSE.

### Official Filings

Neuland Laboratories Limited has disclosed plans for significant future expansion, with its Board of Directors approving a capital expenditure of ₹126 crores on September 7, 2026. This investment is earmarked for the purchase of approximately 134 acres of land in Auro Industrial City, Kakinada, Andhra Pradesh. The company has also secured a right of first refusal for an additional 66 acres, potentially increasing the total land holding to 200 acres. This land acquisition is intended to support future expansion and will be financed through internal accruals.

In parallel, the company has been actively engaging with institutional investors and analysts. Between September 15 and September 25, 2026, Neuland Laboratories management is scheduled to participate in several meetings, including engagements with Emkay Global Investors, ICICI Securities for their Healthcare Day, and the Goldman Sachs Global Healthcare CDMO Day in Singapore. These meetings provide opportunities for the company to discuss its business operations with key market participants.

Separately, an inspection of Neuland Laboratories' Unit 3 manufacturing facility by the US FDA concluded on August 14, 2026. The inspection resulted in one observation related to procedural improvements in water and environmental monitoring. The company has stated it will submit its response to the observation within the stipulated timelines.

- On September 7, 2026, the Board approved a capital expenditure of ₹126 crores to acquire approximately 134 acres of land in Kakinada, Andhra Pradesh, for future expansion, to be funded by internal accruals.
- The company has the option to acquire an additional 66 acres, potentially bringing the total land holding to 200 acres.
- Management participated in investor meetings on September 15 and September 17, 2026, with Emkay Global Investors and ICICI Securities, respectively.
- Management is scheduled to participate in the Goldman Sachs Global Healthcare CDMO Day in Singapore from September 23-25, 2026.
- The US FDA inspection of Unit 3 concluded on August 14, 2026, with one observation regarding procedural improvements in water and environmental monitoring.

- Intimation about Schedule of Analyst / Institutional Investor Meeting on September 23 - 25, 2026 |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- NEULAND LABORATORIES LIMITED has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL
- Neuland Laboratories Limited has informed the Exchange regarding a press release dated September 15, 2026, titled "Press Release". |SUBJECT: Press Release
- NEULAND LABORATORIES LIMITED has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL
- Intimation about Schedule of Analyst / Institutional Investor Meeting on September 15, 2026 and September 17, 2026 |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- Neuland Laboratories Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of SEBI Listing Regulations'. |SUBJECT: Updates
- Neuland Laboratories Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication
- NAME(S)OF THE ACQUIRER AND ITS(PAC) : Malabar India Fund Limited
- Neuland Laboratories Limited has informed the Exchange regarding 'Intimation Regarding Completion Of US FDA Inspection'. |SUBJECT: Updates

### Fundamentals

Neuland Laboratories reported revenue from operations of ₹641.58 crore in Q1 FY2026-27. This follows a significant increase in revenue to ₹776.25 crore in Q4 FY2025-26, compared to ₹439.71 crore in Q3 FY2025-26. The company's profitability has shown a notable upward trend, with Profit Before Tax (PBT) reaching ₹197.85 crore in Q1 FY2026-27, up from ₹287.49 crore in Q4 FY2025-26 and ₹54.48 crore in Q3 FY2025-26. Net profit (Profit Loss For Period) followed a similar pattern, with ₹147.67 crore in Q1 FY2026-27, compared to ₹212.67 crore in Q4 FY2025-26 and ₹40.57 crore in Q3 FY2025-26. Basic Earnings Per Share (EPS) for Q1 FY2026-27 stood at ₹115.10 per share, reflecting the earnings trajectory. The company's tax expense was ₹50.17 crore in Q1 FY2026-27.

- Revenue from operations for Q1 FY2026-27 was ₹641.58 crore.
- Profit Before Tax (PBT) in Q1 FY2026-27 was ₹197.85 crore.
- Profit Loss For Period in Q1 FY2026-27 was ₹147.67 crore.
- Basic Earnings Per Share (EPS) in Q1 FY2026-27 was ₹115.10 per share.
- Tax Expense in Q1 FY2026-27 was ₹50.17 crore.

### Bull Case

Neuland Laboratories has demonstrated significant positive returns over various periods, indicating strong market performance. The company's stock has seen a return of 44% over the past year and 52% year-to-date as of September 18, 2026. Furthermore, a substantial 84% return was observed over the last six months, and a 33% return in the last three months, suggesting sustained upward momentum. Technical indicators also show a bullish trend on weekly and monthly timeframes, with the Supertrend indicator suggesting a bullish direction on both. The company has also operationalized its first commercial peptide manufacturing module, which is expected to expand its production capacity.

- The stock has delivered a 44% return in the past year and 52% year-to-date as of September 18, 2026.
- Recent performance includes an 84% return over the last six months and a 33% return over the last three months.
- Technical indicators show a bullish Supertrend direction on both weekly and monthly charts.
- Neuland Laboratories has commenced operations at its first commercial peptide manufacturing module, enhancing production capabilities.

- Neuland Labs' first commercial peptide manufacturing module goes operational; Stock sees profit booking
- Vijay Kedia reveals multibagger playbook: How the superstar picks stocks using RISE strategy

### Bear Case

The company's stock has experienced a recent drawdown of 5%, indicating a potential cooling off after a period of gains, as evidenced by a 1-month return of -2%. While longer-term returns remain positive, the immediate technical indicators suggest caution. The daily Exponential Moving Average (EMA) of 20 periods is slightly above the closing price, and the slope of the 20-period Simple Moving Average (SMA) over the last 5 days has been negative (-147.45), contrasting with a positive slope for the 50-period SMA. The Average Directional Index (ADX) at 31.55 on a daily timeframe suggests a strong trend, but the proximity of the current price to resistance levels warrants attention.

- The stock has a current drawdown of 5% as of 2026-09-18.
- The 1-month return was -2%, indicating a recent dip in performance.
- Daily technical indicators show the 20-period EMA at 22871.33, slightly above the closing price of 22840.0.
- The 5-day slope of the 20-period SMA is -147.45, suggesting a recent downward price movement on this short-term average.

- Neuland Labs' first commercial peptide manufacturing module goes operational; Stock sees profit booking
- Vijay Kedia reveals multibagger playbook: How the superstar picks stocks using RISE strategy

### FAQs

**What is the significance of Neuland Laboratories' first commercial peptide manufacturing module becoming operational?**

Neuland Laboratories announced that its first commercial peptide manufacturing module is now operational. The company's second module is planned to have a total reactor capacity of up to 18,000 litres, including specific reactor sizes for different manufacturing processes. This development marks a step in the company's manufacturing capabilities.

**What recent investor and analyst interactions has Neuland Laboratories participated in?**

Neuland Laboratories' management participated in several investor and analyst meetings in September 2026. These included a group meeting with Emkay Global Investors on September 15, 2026, and an ICICI Securities Healthcare Day group meet on September 17, 2026. Additionally, the company was scheduled to participate in the Goldman Sachs Global Healthcare CDMO Day in Singapore from September 23-25, 2026, which included a one-on-one meeting with Goldman Sachs analyst Shyam Srinivasan on September 23, 2026.

**How has Neuland Laboratories' stock performed over different periods?**

As of September 18, 2026, Neuland Laboratories has shown varied returns across different timeframes. The stock has returned 44% over the past year and 52% year-to-date. More recently, it has seen a 33% return in the last three months and an 84% return in the last six months. However, the return over the last month was -2%.

**What are the key technical support and resistance levels for Neuland Laboratories as of September 18, 2026?**

As of September 18, 2026, Neuland Laboratories' stock is trading near several technical levels. Key resistance levels identified are at ₹22,921.67 (0.36% higher), ₹23,178.33 (1.48% higher), ₹23,376.67 (2.35% higher), and ₹23,500.00 (2.89% higher). Support levels are noted at ₹22,723.33 (0.51% lower), ₹22,526.00 (1.37% lower), ₹22,466.67 (1.63% lower), and ₹22,268.33 (2.50% lower).

- Neuland Labs' first commercial peptide manufacturing module goes operational; Stock sees profit booking
- Vijay Kedia reveals multibagger playbook: How the superstar picks stocks using RISE strategy
- Intimation about Schedule of Analyst / Institutional Investor Meeting on September 23 - 25, 2026 |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- NEULAND LABORATORIES LIMITED has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL
- Neuland Laboratories Limited has informed the Exchange regarding a press release dated September 15, 2026, titled "Press Release". |SUBJECT: Press Release
- NEULAND LABORATORIES LIMITED has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL
- Intimation about Schedule of Analyst / Institutional Investor Meeting on September 15, 2026 and September 17, 2026 |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
## Technical analytics

- As of: 2026-09-18
- Daily trend: Weak Downtrend
- Weekly trend: Moderate Uptrend
- Pivot point: ₹22,723.33
- Risk regime: Price Risk Requires Attention

### Support levels
- 22526
- 15901.125
- 14840

### Resistance levels
- 23500
- 24051.75
- 22921.666666666664

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | +0.77% |
| return_10 | -0.22% |
| return_1m | -2.27% |
| return_1y | +43.89% |
| return_20 | -3.09% |
| return_3m | +32.64% |
| return_5 | -4.03% |
| return_6m | +84.00% |
| return_since_start | +59.79% |
| return_ytd | +51.66% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | elevated_risk |
| label | Price risk requires attention |
| summary | Recent drawdown or price variability is high enough to warrant closer monitoring. |
| maximum_drawdown | -36.21% |
| annualized_volatility | +45.51% |

## Quarterly financials

- Latest complete quarter: fy27_q1

# Revenue and Profit Expand Year-Over-Year Amid Sequential Decline

Neuland Laboratories reported revenue of ₹641.58 crore and net profit of ₹147.67 crore for the first quarter of FY2026-27. Both figures more than doubled compared to the same quarter last year, though they declined sequentially from the prior quarter's results. Profit margins widened significantly on a year-over-year basis but contracted slightly compared to the previous quarter.

## Revenue
Revenue from operations reached ₹641.58 crore in the current quarter, up 119% from ₹292.75 crore a year ago. This represents a ₹348.82 crore absolute increase. On a sequential basis, revenue fell 17% from ₹776.25 crore in the fourth quarter of FY2025-26. The current quarter's revenue ranks as the second highest among the five available quarters, trailing only the prior quarter.

## Profitability and Margins
Profit before tax stood at ₹197.85 crore, a 1,026% increase from ₹17.57 crore a year ago and a 31% decrease from ₹287.49 crore in the prior quarter. After accounting for a tax expense of ₹50.17 crore, which implies an effective tax rate of 25.4%, net profit came in at ₹147.67 crore. This marks a 962% year-over-year rise from ₹13.90 crore and a 31% sequential drop from ₹212.67 crore.

The net profit margin expanded to 23.0% in the current quarter, compared to 4.7% a year ago. However, this represents a contraction from the 27.4% margin recorded in the prior quarter. The year-over-year margin expansion occurred because revenue grew at a faster pace than total expenses over the twelve-month period.

## Expenses
Total expenses were ₹452.22 crore, up 60% from ₹283.04 crore a year ago and down 10% from ₹501.21 crore in the fourth quarter. The sequential decline in expenses was smaller in percentage terms than the sequential decline in revenue, which contributed to the slight compression in profit margins compared to the prior quarter. 

Profit before tax of ₹197.85 crore exceeded the difference between revenue and total expenses (₹189.36 crore) by ₹8.49 crore. This difference aligns with the reported other income of ₹8.49 crore for the quarter, which added directly to pre-tax earnings.

## Earnings Per Share
Basic and diluted earnings per share were both ₹115.10. This compares to ₹10.83 a year ago, representing a 963% increase, and ₹165.76 in the prior quarter, reflecting a 31% sequential decline.

## Management Commentary

Management reported Q1FY27 was broadly in line with expectations, with both CMS and GDS businesses showing encouraging performance. While commercial products drove most revenue, the company highlighted exciting developments in its pipeline projects and noted that customer conversations are now significantly deeper, focusing on broader capability-led discussions rather than individual projects. Management emphasized that the intensity of investments will further increase based on the opportunities available, and all significant Capex projects are proceeding as planned. Working capital days improved to 84 from 137 in Q4FY26, and net debt turned negative at Rs -308.5 crore, reflecting a strong cash position.

Neuland announced a strategic partnership with Gland Pharma to establish a sterile API manufacturing suite for microparticle depot products, combining Neuland's complex API expertise with Gland's sterile manufacturing capabilities. The suite will add approximately 1,400 kg of annual capacity to serve growing global demand for sterile APIs. Separately, the Board approved a capacity expansion of 18 KL at Unit 1 (current utilization 91%) with an investment of Rs 39.8 crore, financed through internal accruals, to meet increasing customer demand. The CMS pipeline remains robust with 99 active projects, including 19 at commercial stage, and traction is building with innovators for peptide molecules.

## Key Takeaway
Neuland Laboratories delivered substantial year-over-year growth in revenue and profit for the first quarter of FY2026-27, with both metrics more than doubling from the same period last year. The sequential decline from the prior quarter reflects a step-down from a higher baseline. Profitability margins remain well above year-ago levels despite a slight sequential contraction, driven by revenue growth outpacing expense growth over the twelve-month period.

### Ratios

## Official filings

- 2026-09-16 — Generic Announcement: Neuland Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/NEULANDLAB_16092026161136_SignedSE_Intimation.pdf)
- 2026-09-16 — Generic Announcement: Neuland Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_465_WebXMLFile_20260916_161456415.xml)
- 2026-09-15 — Press Release: Neuland Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/NEULANDLAB_15092026102537_SignedSEIntimation15092026.pdf)
- 2026-09-09 — Generic Announcement: Neuland Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_465_WebXMLFile_20260909_181250345.xml)
- 2026-09-09 — Generic Announcement: Neuland Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/NEULANDLAB_09092026180628_SignedSE_Intimation09092026.pdf)
- 2026-09-09 — Generic Announcement: Neuland Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_465_WebXMLFile_20260909_181954234.xml)
- 2026-09-07 — Generic Announcement: Neuland Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/NEULANDLAB_07092026172307_SignedSEIntimation_Final.pdf)
- 2026-08-23 — Generic Announcement: Neuland Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/NEULANDLAB_23082026195217_SignedSEIntimationSpecialWindow.pdf)
- 2026-08-18 — Regulatory Filing: Neuland Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/NEULANDLAB_08182026191355_52732.zip)
- 2026-08-14 — Generic Announcement: Neuland Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/NEULANDLAB_14082026185110_SignedSEIntimationFDA_Unit3.pdf)
- 2026-08-10 — Generic Announcement: Neuland Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_465_WebXMLFile_20260810_194023656.xml)
- 2026-08-10 — Press Release: Neuland Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/NEULANDLAB_10082026185418_SignedSEIntimationTranscript.pdf)
- 2026-08-07 — Generic Announcement: Neuland Laboratories Limited management will participate in the Emkay Confluence 2026 event in Mumbai on August 12, 2026, involving group and one-on-one meetings with analysts and institutional investors. The schedule and participant list are subject to change. — [Official attachment](https://nsearchives.nseindia.com/corporate/NEULANDLAB_07082026134301_SignedSEIntimation.pdf)
- 2026-08-07 — Generic Announcement: Neuland Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_465_WebXMLFile_20260807_135024438.xml)
- 2026-08-06 — Generic Announcement: Neuland Laboratories Limited has published its financial results for the quarter ended June 30, 2026, in the Financial Express and Nava Telangana newspapers on August 6, 2026, as per SEBI regulations. The filing also includes separate news items regarding Telangana's electricity consumption, a tribute to former Chief Minister Jayashankar, and a report on the state's industrial development. — [Official attachment](https://nsearchives.nseindia.com/corporate/NEULANDLAB_06082026100205_SignedSEIntimationFRAdv.pdf)
- 2026-08-05 — Earnings Presentation: Neuland Laboratories Limited announced its financial results for the quarter ended June 30, 2026, reporting total income of Rs. 650.1 crore, a 116.3% year-over-year increase. EBITDA was Rs. 231.1 crore, up 448.2% YoY, with an EBITDA margin of 35.5%. Profit After Tax (PAT) reached Rs. 147.4 crore, a 975.0% YoY increase. The company also reported a Capex outflow of Rs. 122 crore for the quarter and a net debt of Rs. (308.5) crore. — [Official attachment](https://nsearchives.nseindia.com/corporate/NEULANDLAB_05082026162323_SignedInvestorsAnalystsPresentation.pdf)
- 2026-08-05 — Press Release: Neuland Laboratories Limited reported financial results for the quarter ended June 30, 2026, with total income at Rs. 650.1 crore and EBITDA at Rs. 231.1 crore. The company noted encouraging performance from its CMS & GDS businesses and significant investments in Capex projects. — [Official attachment](https://nsearchives.nseindia.com/corporate/NEULANDLAB_05082026161549_SignedPressRelease.pdf)
- 2026-08-05 — Official Filing: Neuland Laboratories Limited announced on August 5, 2026, a board-approved capacity addition of 18 KL to its existing 376.5 KL capacity, with an investment of INR 398,000,000 to be financed through internal accruals. This expansion, aimed at meeting growing customer demand, is expected to be completed within 6-7 months.
- 2026-08-05 — Generic Announcement: Neuland Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_465_WebXMLFile_20260805_222702409.xml)
- 2026-08-05 — Generic Announcement: On August 5, 2026, Neuland Laboratories Limited's Board of Directors approved unaudited financial results for the quarter ended June 30, 2026, and a corporate guarantee of ₹40 crores for Gland Pharma Limited to establish dedicated manufacturing capacity. The company also approved an investment of ₹39.8 crores to enhance manufacturing capacity at its Unit 1 facility, adding 18 KL over 6-7 months, financed through internal accruals. — [Official attachment](https://nsearchives.nseindia.com/corporate/NEULANDLAB_05082026163655_SignedSEIntimation.pdf)
- 2026-08-05 — Generic Announcement: On August 5, 2026, Neuland Laboratories Limited's Board of Directors approved unaudited financial results for the quarter ended June 30, 2026, and a corporate guarantee of ₹40 crores for Gland Pharma Limited to establish dedicated manufacturing capacity. The company also approved an investment of ₹39.8 crores to enhance manufacturing capacity at its Unit 1 facility, adding 18 KL over 6-7 months, financed through internal accruals. — [Official attachment](https://nsearchives.nseindia.com/corporate/NEULANDLAB_05082026163040_SignedSEIntimation.pdf)
- 2026-08-05 — Official Filing: On August 5, 2026, Neuland Laboratories Limited's Board of Directors approved the execution of an irrevocable, unconditional, and continuing Corporate Guarantee of INR 40 crores in favor of Gland Pharma Limited. This guarantee is in connection with Neuland Laboratories' obligations under a future Loan Licence Agreement, securing due payment and performance related to Gland Pharma's establishment of dedicated manufacturing capacity and capital expenditure. The guarantee represents a contingent liability with no immediate financial impact.
- 2026-08-05 — Generic Announcement: Neuland Laboratories Limited has provided a link to the audio recording of its earnings call for the quarter ended June 30, 2026. The call was conducted on August 5, 2026, in compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. — [Official attachment](https://nsearchives.nseindia.com/corporate/NEULANDLAB_05082026222005_SignedSEIntimationaudiorecording.pdf)
- 2026-08-05 — Generic Announcement: On August 5, 2026, Neuland Laboratories Limited's Board of Directors approved unaudited financial results for the quarter ended June 30, 2026, and a corporate guarantee of ₹40 crores for Gland Pharma Limited to establish dedicated manufacturing capacity. The company also approved an investment of ₹39.8 crores to enhance manufacturing capacity at its Unit 1 facility, adding 18 KL over 6-7 months, financed through internal accruals. — [Official attachment](https://nsearchives.nseindia.com/corporate/NEULANDLAB_05082026155912_SignedSEIntimation.pdf)
- 2026-08-04 — Generic Announcement: Neuland Laboratories Limited held its 42nd Annual General Meeting on August 4, 2026, conducted via video conferencing. All seven ordinary resolutions, including the adoption of financial statements for the year ended March 31, 2026, the declaration of a final dividend of Rs. 34.00 per equity share, the re-appointment of Dr. Davuluri Rama Mohan Rao, payment of commission to non-executive directors, appointment of Dr. Mauricio Futran as a director, payment of professional fees to Dr. Futran, and ratification of cost auditors' remuneration, were passed by the requisite majority. The meeting was attended by 81 members. — [Official attachment](https://nsearchives.nseindia.com/corporate/NEULANDLAB_04082026173627_SignedSEIntimationAGMOutcome4Aug2026.pdf)

## News and market events

- 2026-09-15 — CNBC-TV18: **Neuland Labs' first commercial peptide manufacturing module goes operational; Stock sees profit booking** — Neuland Labs' second module is planned to have a total reactor capacity of up to 18,000 litres. It will include three 5,000-litre LPPS reactors, either a 1,000-litre or 2,000-litre SPPS reactor, and smaller reactors of up to 1,000 litres. — [Source](https://www.cnbctv18.com/market/neuland-labs-share-price-first-commercial-peptide-manufacturing-module-goes-operational-capacity-expansion-api-19990722.htm)
- 2026-09-15 — Economic Times: **Vijay Kedia reveals multibagger playbook: How the superstar picks stocks using RISE strategy** — Vijay Kedias investment approach is built as much around discipline as opportunity. He is willing to buy stocks after sharp declines but refuses to chase them when valuations move beyond his comfort zone. As mutual funds, family offices and other investors crowd into emerging businesses, Kedia is increasingly looking at SMEs, unlisted companies and startups for opportunities that offer attractive valuations and growth potential. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/vijay-kedia-reveals-multibagger-playbook-how-the-superstar-picks-stocks-using-rise-strategy/articleshow/134251870.cms)
- 2026-09-08 — BUSINESS: **Stock Alert: Swiggy, Shiprocket, Neuland Lab, PNB Housing Finance** — Shares of Inox Wind, Kaynes Technology, LIC Housing Finance and SAIL barred from fresh F&O positions on 7 September 2026. — [Source](https://www.business-standard.com/markets/capital-market-news/stock-alert-swiggy-shiprocket-neuland-lab-pnb-housing-finance-126090800124_1.html)
- 2026-09-07 — FREEPRESSJOURNAL.IN: **Neuland Laboratories Approves ₹126 Crore Investment, Buys 134 Acres For Future Expansion** — Neuland Laboratories will invest Rs 126 crore to acquire 134 acres in Kakinada, with an option for 66 more acres, to support future expansion. — [Source](https://www.freepressjournal.in/business/neuland-laboratories-approves-126-crore-investment-buys-134-acres-for-future-expansion)
- 2026-09-07 — CNBC-TV18: **Neuland Labs clears ₹126 crore capex for 134 acres of land in Andhra Pradesh’s Kakinada** — Shares of Neuland Laboratories Ltd ended at ₹22,955.00, up by ₹311.70, or 1.38%, on the BSE. — [Source](https://www.cnbctv18.com/market/stocks/neuland-labs-share-price-clears-rs-126-crore-capex-for-134-acres-of-land-in-andhra-pradeshs-kakinada-19985842.htm)
- 2026-09-07 — Economic Times: **Exclusive | How Vijay Kedia turned a Rs 250 Neuland Labs bet into nearly 100x returns** — Investor Vijay Kedia's savvy investment in Neuland Laboratories has paid off handsomely, yielding nearly 100x returns. He seized the opportunity during the Covid downturn when stock prices dipped. By concentrating on the companys promising peptide sector and its CDMO capabilities, Kedia emphasized his tactic of investing in overlooked firms with solid fundamentals, which has ultimately fostered substantial wealth growth over the years. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/exclusive-how-vijay-kedia-turned-a-rs-250-neuland-labs-bet-into-nearly-100x-returns/articleshow/133862493.cms)
- 2026-08-06 — CNBC-TV18: **From Trent and Britannia to LIC: Thursday's biggest earnings winners, losers and surprises** — Retail, FMCG, insurance and pharma dominated another busy day of results, but the biggest market moves came from the details hidden beneath the headline numbers. — [Source](https://www.cnbctv18.com/market/earnings/trent-britannia-lic-earnings-aug-6-biggest-q1-results-winners-losers-and-surprises-19963637.htm)
- 2026-08-06 — The Hindu: **Sensex today | Stock Market Live: Sensex rises 250 pts, Nifty holds 24,600 on US-Iran peace hopes, RBI outlook; Neuland Lab shares up 9.6%** — Sensex, Nifty, Share Prices LIVE: Sensex was up 160.95 pts or 0.20% to 78,741.95 at 9.16 am after opening at 78,782.43 from the previous close of 78,581; Nifty inched up 8.70 pts or 0.04% to 24,633.35. — [Source](https://www.thehindubusinessline.com/markets/sensex-nifty50-today-stock-market-live-updates-6-august-2026/article71309748.ece)
- 2026-08-06 — The Hindu: **Q1 Results Today Live: Trent, Hero MotoCorp, Lupin, Britannia, Siemens Energy, LIC, BOSCH, Kirloskar Oil Engines, Aegis Logistics, Premier Energies, Emcure Pharma to announce Q1 results, Biocon, Berger Paints, Neuland Lab, ArisInfra gain, Aurobindo Pharma, Aster DM, Whirlpool, PB Fintech, Power Grid, Godrej Agrovet in red after Q1** — Q1 Results Today, 06th August 2026 Live Updates: Follow Q1FY27 live updates frmo businessline — [Source](https://www.thehindubusinessline.com/markets/q1-results-today-live-updates-trent-britannia-siemens-energy-hero-motocorp-lupin-lic-kirloskar-oil-engines-bosch-aegis-logistics-premier-energies-emcure-pharma-blue-star-results-06-august-2026/article71312019.ece)
- 2026-08-06 — CNBC-TV18: **Sensex Today | Stock Market LIVE Updates: Nifty slips below 24,650; Power Grid down 2.50%** — Sensex Today | Stock Market LIVE Updates: Sensex contracts face weekly expiry, testing the CAS system. Nifty defended 24,500, Nifty Bank defended 57,500. Over 50 major results are due today. — [Source](https://www.cnbctv18.com/market/stock-market-live-updates-sensex-nifty-50-today-hdfc-bank-aurobindo-cummins-biocon-pb-fintech-lic-trent-share-price-liveblog-19962846.htm)
- 2026-08-06 — CNBC-TV18: **Neuland Labs shares surge 10% after Q1 results better analyst expectations, strong commentary** — All four analysts tracking Neuland Laboratories have a "buy" rating on it. The consensus estimate of price targets implies an upside potential of 18% from current levels. JM Financial has the highest price target on the street for the stock at ₹25,819. — [Source](https://www.cnbctv18.com/market/neuland-laboratories-share-price-q1-result-reaction-revenue-margins-buy-sell-2026-returns-19962932.htm)
- 2026-08-06 — CNBC-TV18: **Q1 Results LIVE Updates: Neuland Labs shares surge 10%; Cummins, GE Vernova fall 6% each** — Q1 Results LIVE Updates; Trent, Britannia, Lupin, Samvardhana Motherson, Apollo Tyres, Blue Star, Premier Energies, HCC, NCC, PG Electroplast, Emcure Pharma, Firstsource Solutions are some of the many companies that will be reporting their results during the course of Thursday's trading session on Dalal Street. Result reactions today come from PB Fintech, Aurobindo Pharma, Cummins India, GE Vernova T&D, ION Exchange and many others. Watch this space for all the LIVE Q1 result updates, management and brokerage commentary along with stock moves. — [Source](https://www.cnbctv18.com/market/q1-results-live-updates-cummins-ge-vernova-td-pb-fintech-trent-britannia-hero-lupin-samil-pgel-apollo-tyres-sci-ncc-hcc-premier-energies-share-price-liveblog-19962840.htm)
- 2026-08-05 — DECCANCHRONICLE.COM: **Gland Pharma, Neuland Laboratories Strategic Collab for Sterile API Manufacturing** — Partnership to expand sterile API manufacturing through a new, cGMP state-of-the-art sterile suite — [Source](https://www.deccanchronicle.com/nation/in-other-news/gland-pharma-neuland-laboratories-strategic-collab-for-sterile-api-manufacturing-1976920)
- 2026-08-05 — CNBC-TV18: **Stocks to Watch for August 6: Cummins India, Biocon, PB Fintech and more** — Stocks such as Navin Fluorine International, Cummins India, PB Fintech, JK Lakshmi Cement, Neuland Laboratories and Aster DM Quality Care will be in focus on Thursday after reporting their June-quarter earnings post market hours on Wednesday. Investors will also track companies scheduled to announce their June-quarter results during the day for stock-specific cues. — [Source](https://www.cnbctv18.com/photos/market/stocks-to-watch-for-august-6-cummins-india-biocon-pb-fintech-and-more-19962532.htm)

## Business profile

**Strategic vision:** Global CDMO specializing in Active Pharmaceutical Ingredients (APIs).

### Business segments
- **Generic APIs:** Neuland Laboratories develops and manufactures non-exclusive APIs, including large-volume 'Prime APIs' and lower-volume, complex 'Specialty APIs'.
- **CDMO Services:** These services cover the entire lifecycle of drug development, from initial stages to commercial production, including process development, optimization, analytical testing, and regulatory support.
- **Peptide Development:** Neuland Laboratories provides development and manufacturing services for peptides, ranging from milligram to multi-kilogram scales using chemical synthesis strategies.

### Competitive strengths
- Expertise in overcoming chemistry challenges in drug development.
- Legacy as a pure-play API manufacturer since 1984.

## Related stocks

- [ABBOTINDIA (Healthcare)](https://faxioms.com/stocks/abbotindia) — +5.50%
- [ACUTAAS (Healthcare)](https://faxioms.com/stocks/acutaas) — +3.86%
- [AJANTPHARM (Healthcare)](https://faxioms.com/stocks/ajantpharm) — +1.61%
- [ALKEM (Healthcare)](https://faxioms.com/stocks/alkem) — +0.14%
- [ANTHEM (Healthcare)](https://faxioms.com/stocks/anthem) — -0.35%

## Freshness and sources

- Data as of: 2026-09-18
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/neulandlab
Markdown representation: https://faxioms.com/stocks/neulandlab?render=md